Good MorningThe rally on Wall Street hit another roadblock on Thursday despite better-than-expected economic data. The data included ISM services and factory orders which both came in better than expected. The news sent the S&P 500 up in early trading but resistance capped the gains at the key 4,150 level. If the market can not get above this level soon another round of selling could follow and there is a catalyst due out on Friday.
The NFP report is expected to show a slowdown in hiring that is also foreshadowed by the jobless claims data. The number of initial and total claims for unemployment continues to rise and suggests a topping in the labor markets. Topping in the labor market is good news for inflation but bad news for the economy because it will undercut consumer spending growth and weigh on the outlook for economic activity and corporate earnings. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Consumer Staples | |
Membership warehouse club operator BJ’s Wholesale Club Holdings (NYSE: BJ) stock is one of the rare stocks actually trading up 3% for 2022. Rising inflation and fuels prices have driven the consumers to warehouse clubs away from traditional retailers as households tighten their budgets. BJ&r... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Materials | |
MarketBeat reported that Freeport McMoran Inc (NYSE: FCX) submitted its earnings card this week. The results were mixed, with the company's net income contracting $840M from $1083M last year. The company's EPS also shrank from 0.57 to 73 cents from the same quarter last year. On a positive note, c... Read the Full Story |
|
Markets | |
Although not back to pre-pandemic levels, occupancy rates at many hotel chains are recovering. That’s the conclusion of Smith Travel Accommodations Research (STR). In the same survey, the research firm concluded that RevPAR (revenue per available room) and ADR (average daily rate) are also o... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Industrials | |
FuelCell Energy (NASDAQ: FCEL) along with other stocks in the industrial sector was sold off recently following the news that the US senate would not sponsor a package that would introduce new spending to tackle climate change. Since then, the stock is currently up 2.34%, so some investors have wo... Read the Full Story |
|
Consumer Discretionary | |
It hasn’t been an incredibly fun year for investors in Cedar Fair (NYSE: FUN) stock. The company’s share price is down 19.5% for the year. And that loss is even worse for investors who entered a position when the stock was at its 52-week high in mid-February.
But after the amusement... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
Nikola (NASDAQ: NKLA) delivered better-than-expected results during the second-quarter, as the company produced over 50 Nikola TRE Bevs during the quarter and delivered over 48 to dealers. The company remains on track to deliver 300-500 trucks during the fiscal year and continues to see significan... Read the Full Story |
|
Energy | |
Insider buying has been picking up with stocks from all sectors and industries going on sale. While the list of stocks with insider buying is long, the three top names in July are Occidental Petroleum, Rocket Companies, and Comtech. These are the top names because their activity is not only high b... Read the Full Story |
|
Consumer Staples | |
Church & Dwight (NYSE: CHD) might not exactly be a household name, but you've likely heard of many of the company's brands: ARM & HAMMER, Trojan, First Response, Nair, Spinbrush, OxiClean, Orajel, Vitafusion, WaterPik and ZICAM.
If you already know some of the company's powerhouse brands,... Read the Full Story |
|
Consumer Discretionary | |
If you’re trying to decide between investment in Chipotle Mexican Grill (NYSE: CMG) or Shake Shack (NYSE: SHAK) the results may be the only information you need. On the one hand, we have another name in hamburgers trying to reinvent the wheel and having a hard time with it while on the other... Read the Full Story |
|
Markets | |
While the market waits on regulatory approval of Microsoft’s (NASDAQ: MSFT) takeover, Activision Blizzard (NASDAQ: ATVI) is on the verge of releasing a flurry of new content that should drive results in Q3 and Q4. Benchmark noted the content and called it a “significant” second-h... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. | | View Today's Stock Pick |
|
